Immunic Stock Surges Following Guggenheim Buy Recommendation

AI Summary

Immunic's stock experienced a notable increase after Guggenheim initiated coverage with a 'Buy' rating. This development signals confidence in the company's potential, likely impacting investor sentiment and trading volumes. Specific percentage changes or trading volume data were not provided in the article, but the initiation of coverage by a significant firm indicates a positive outlook for the stock's future performance. This move may lead to increased market interest in Immunic shares.